Clene Inc.
NASDAQ:CLNN
Gross Margin
Clene Inc.
Gross Margin is the amount of money a company retains after incurring the direct costs associated with producing the goods it sells and the services it provides. The higher the gross margin, the more capital a company retains, which it can then use to pay other costs or satisfy debt obligations.
Gross Margin Across Competitors
| Country | Company | Market Cap |
Gross Margin |
||
|---|---|---|---|---|---|
| US |
|
Clene Inc.
NASDAQ:CLNN
|
87.7m USD |
80%
|
|
| FR |
|
Pharnext SCA
OTC:PNEXF
|
6T USD |
0%
|
|
| US |
|
Abbvie Inc
NYSE:ABBV
|
414.2B USD |
71%
|
|
| US |
|
Amgen Inc
NASDAQ:AMGN
|
180.4B USD |
72%
|
|
| US |
|
Gilead Sciences Inc
NASDAQ:GILD
|
158.2B USD |
79%
|
|
| US |
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
109B USD |
86%
|
|
| US |
E
|
Epizyme Inc
F:EPE
|
94.1B EUR |
76%
|
|
| US |
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
81.1B USD |
86%
|
|
| AU |
|
CSL Ltd
ASX:CSL
|
88.6B AUD |
52%
|
|
| US |
|
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
|
57.2B USD |
84%
|
|
| NL |
|
argenx SE
XBRU:ARGX
|
48.5B EUR |
90%
|
Clene Inc.
Glance View
Clene, Inc. is a clinical-stage biopharmaceutical company, which focuses on the development of therapeutics for neurodegenerative diseases. The company is headquartered in Salt Lake City, Utah and currently employs 95 full-time employees. The company went IPO on 2018-08-27. The firm is focused on the treatment of neurodegenerative disease with potential first-in-class nanotherapeutics to treat energetic failure and neurological diseases. The Company’s lead drug candidate, CNM-Au8, is an oral suspension of gold nanocrystals that drive critical cellular energetic metabolism in the central nervous system (CNS). CNM-Au8 increases energy production and utilization to accelerate neurorepair and improve neuroprotection. CNM-Au8 is being evaluated in a Phase III registration trial in amyotrophic lateral sclerosis (ALS) and a Phase II trial for the treatment of chronic optic neuropathy in patients with stable relapsing multiple sclerosis (MS). The firm has also advanced into the clinic an aqueous solution of ionic zinc and silver for anti-viral and anti-microbial uses.
See Also
Gross Margin is the amount of money a company retains after incurring the direct costs associated with producing the goods it sells and the services it provides. The higher the gross margin, the more capital a company retains, which it can then use to pay other costs or satisfy debt obligations.
Based on Clene Inc.'s most recent financial statements, the company has Gross Margin of 80.4%.